Rifalazil and Derivative Compounds Show Potent Efficacy in a Mouse Model of H. pylori Colonization

Rothstein, David M.; Mullin, Steve; Sirokman, Klari; Søndergaard, Karen; Johnson, Starrla; Gwathmey, Judith K.; Duzer, John van; Murphy, Christian

doi:10.1038/ja.2008.64

J Antibiot

2008

DOI: 10.1038/ja.2008.64

|View full text |Cite

Rifalazil and Derivative Compounds Show Potent Efficacy in a Mouse Model of H. pylori Colonization

David M. Rothstein

Steve Mullin

Klari Sirokman³

et al.

Abstract: The rifamycin rifalazil (RFZ), and derivatives (NCEs) were efficacious in a mouse model of Helicobacter pylori colonization. Select NCEs were more active in vitro and showed greater efficacy than RFZ. A systemic component contributes to efficacy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

2014

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Recent derivatives from smaller classes of fermentation-derived antibacterials

Kirst

2011

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

Following the regulatory approvals of daptomycin and retapamulin for human use, these renewed investigations of underdeveloped fermentation-derived classes have demonstrated the further potential to discover new clinical candidates. However, many other classes of natural product antibiotics still remain underinvestigated and are thus available for renewed examinations. This strategy is one means for finding new antibiotics to add to the physician's armamentarium for treating resistant pathogens.

show abstract

Recent derivatives from smaller classes of fermentation-derived antibacterials

Kirst

2011

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

show abstract

Novel Anti -Helicobacter Pylori Therapies

Shahid¹

2014

Pharm. Pat. Anal.

View full text Add to dashboard Cite

Helicobacter pylori is a ubiquitous gastropathogen infecting more than half of the world population. It is associated with dyspepsia, gastritis, gastroduodenal ulcers, mucus-associated lymphoid tissue lymphoma and gastric carcinoma. Current recommended therapy does not eradicate infection in all treated cases and at least 20% post-treatment patients continue to suffer. Salvage therapy helps some of these nonresponders, but resistance to available antibiotics is mounting. Hence, its treatment still remains a daunting task for the practicing physician. Novel medications with improved efficacy and tolerability and with less chances of resistance are required. The present review attempts to discuss the newer patents in this field, which demonstrate a promising future role in the management of H. pylori infection and its consequent problems.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Rifalazil and Derivative Compounds Show Potent Efficacy in a Mouse Model of H. pylori Colonization

Abstract: The rifamycin rifalazil (RFZ), and derivatives (NCEs) were efficacious in a mouse model of Helicobacter pylori colonization. Select NCEs were more active in vitro and showed greater efficacy than RFZ. A systemic component contributes to efficacy.

Cited by 2 publications

References 16 publications

Recent derivatives from smaller classes of fermentation-derived antibacterials

Recent derivatives from smaller classes of fermentation-derived antibacterials

Novel Anti -Helicobacter Pylori Therapies

Contact Info

Product

Resources

About